Briacell Therapeutics Corp (BCTX)

US · Healthcare · Biotechnology

$4.22+18.54%

Last close · 2026-09-17

Latest quarter · ended 2026-04-30

Revenue

Net profit

$-7.2M

EPS

$-0.99

Market cap

$31.0M

Forward P/E

0.0

P/B

1.29

Book value

$3.32

EPS (TTM)

$-0.84

52-week high

$14.68

52-week low

$2.60

50-day MA

$3.62

200-day MA

$4.67

Beta

1.53

Analysts rate Briacell Therapeutics Corp a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $150.00.

Insiders

0.51%

Institutions

6.39%

Fund	Stake
Cable Car Capital LLC	2.49%
Sabby Management LLC	0.85%
Iridian Asset Management LLC	0.75%
LuminArx Capital Management LP	0.17%
UBS Group AG	0.13%
Morgan Stanley - Brokerage Accounts	0.03%
NATIONAL BANK OF CANADA /FI/	0.02%
Federation des caisses Desjardins du Quebec	0.01%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Briacell Therapeutics Corp — free to start.

Data updated 2026-09-18.